Theralase Validates Herpes Treatment with Ruvidar™

Theralase Technologies Inc. has confirmed the efficacy and safety of Ruvidar™ in treating the Herpes Simplex Virus Type 1 (HSV-1) in an animal model. The study builds on previous research from the University of Manitoba, indicating promising results in the inactivation of the virus. HSV, a common infection causing painful blisters, affects over 3.8 billion people globally. While current treatments exist, HSV remains incurable.

The HSV treatment market, valued at $2.5 billion in 2023, is projected to grow significantly, driven by the demand for more effective therapies. North America holds a significant market share due to higher consumption of herpes drugs and supportive healthcare policies.

The recent experiment involved applying a 1% Ruvidar™ solution to HSV-1 lesions in mice, resulting in complete healing within four days. Theralase plans to pursue clinical development of vaccines and therapeutics for HSV, aiming to address the unmet needs of millions affected worldwide.